Multiple Myeloma Plasma Cell Kinetics: Rapid and Reliable Evaluation using 5-Bromo-2-Deoxyuridine (BrdUrd) DNA Incorporation Detected by an Anti-BrdUrd Monoclonal Antibody
Restricted accessResearch articleFirst published online April, 1986
Multiple Myeloma Plasma Cell Kinetics: Rapid and Reliable Evaluation using 5-Bromo-2-Deoxyuridine (BrdUrd) DNA Incorporation Detected by an Anti-BrdUrd Monoclonal Antibody
In 19 patients with monoclonal gammopathy, plasma cell proliferative activity was evaluated using 5-bromo-2-deoxyuridine (BrdUrd) incorporation, as revealed by an anti-BrdUrd monoclonal antibody. A simultaneous standard labelled thymidine incorporation was carried out in all patients as reference test. The BrdUrd method was confirmed as a reliable test and is recommended for routine clinical application in monoclonal gammopathies.
Get full access to this article
View all access options for this article.
References
1.
BoccadoroM., GavarottiP., FossatiG., MassaiaM., PileriA., DurieB.G.M.: Kinetics of circulating B lymphocytes in human myeloma.Blood, 61: 812–814, 1983.
2.
BoccadoroM., GavarottiP., FossatiG., PileriA., MarmontF., NerettoG., GallaminiA., VoltaC., TribaltoM., TestaM.G., AmadoriS., MandelliF., DurieB.G.M.: Low plasma cell [3H] thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.Br. J. Hemaetol., 58: 689–696, 1984.
3.
BoccadoroM., GallaminiA., FrutteroA., GavarottiP., RedogliaV., BuffaF., RuàS., PileriA.: Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine labelling index.J. Clin. Oncol., 3: 1503–1507, 1985.
4.
CostaA., BonadonnaG., VillaE., ValagussaP., SilvestriniR.: Labelling index as prognostic marker in non-Hodgkin's lymphomas.J. Natl. Cancer Inst., 66: 1–5, 1981.
5.
DurieB.G.M., SalmonS.E.: High speed scintillation autoradiography.Science, 190: 1093–1095, 1975.
6.
DurieB.M.G., SalmonS.E.: Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Recent Advances in Haematology.HoffbrandA.V., BrownM.C., and HirschJ. (Eds.), pp. 243–261, Churchill Livingstone, Edinburgh, 1977.
7.
DurieB.M.G., SalmonS.E., MoonT.E.: Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.Blood, 55: 364–372, 1980.
8.
GratznerH.G.: Monoclonal antibodies to 5-bromo and 5-iododeoxyuridine: a new reagent for detection of DNA replication.Science, 218: 474–475, 1982.
9.
GreippP.R., KyleR.A.: Clinical, morphological, and cell kinetic differences among myeloma, monoclonal gammopathy of undetermined significance, and smoldering myeloma.Blood, 62: 166–171, 1983.
10.
PileriA., CarmagnolaA., BoccadoroM.: Human myeloma: kinetics of the remission phase.Acta Haematologica, 68: 237–240, 1982.
11.
SilvestriniR., DaidoneM.G., CostaA., SanfilippoO.: Cell kinetics and in vitro chemosensitivity as a tool for improved management of patients.Eur. J. Cancer Clin. Oncol., 21: 371–378, 1985.
